Back to news
Novartis faces setbacks in drug development
ONE REPORT·Published ·Event date ·Main source · Handelsblatt
Story essentials
Novartis
Switzerland
June 2026
Original reports
Novartis reported a failure in a key clinical trial for the drug Del-Desiran, intended for a rare muscle disease.
This follows the recent failure of a major cholesterol medication, causing a 10% drop in Novartis shares.
Del-Desiran was a central component of the 12 billion dollar acquisition of Avidity Biosciences.
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
Construction industry faces downturn amid rising tariffs and labor shortages
U.S. construction activity has slowed due to rising material costs and labor shortages. New 50% tariffs on Canadian construction goods enacted on August 21, 2025, are impacting project budgets. Developers are struggling with increased costs for materials like lumber, cement, and steel.